MedTrace Logo

Gene Therapy(FT-003) for Wet AMD

NCT06492863 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2024-07-09

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of disposable vitreous injection of FT-003 in subjects with neovascular age-related Macular Degeneration (nAMD). The study was divided into two phases, Phase 1 dose escalation and Phase II dose expansion.

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

GENETIC

FT-003

Administered via intraocular injection.

Sponsors & Collaborators

  • Tianjin Medical University Eye Hospital

    collaborator OTHER

  • The First Affiliated Hospital of Soochow University

    collaborator OTHER

  • Peking Union Medical College Hospital

    collaborator OTHER

  • Beijing Hospital

    collaborator OTHER_GOV

  • Frontera Therapeutics

    lead INDUSTRY

Principal Investigators

  • Xiaorong Li, Professor · Tianjin Medical University Eye Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-15
Primary Completion
2024-10-15
Completion
2028-10-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06492863 on ClinicalTrials.gov